| MeSH term | MeSH ID | Detail |
|---|---|---|
| Connective Tissue Diseases | D003240 | 2 associated lipids |
| Corneal Diseases | D003316 | 13 associated lipids |
| Cough | D003371 | 19 associated lipids |
| Crigler-Najjar Syndrome | D003414 | 1 associated lipids |
| Crohn Disease | D003424 | 12 associated lipids |
| Cryptococcosis | D003453 | 3 associated lipids |
| Cutis Laxa | D003483 | 1 associated lipids |
| Cystic Fibrosis | D003550 | 65 associated lipids |
| Cystitis | D003556 | 23 associated lipids |
| Phyllodes Tumor | D003557 | 1 associated lipids |
| Hearing Loss, Sudden | D003639 | 1 associated lipids |
| Deglutition Disorders | D003680 | 2 associated lipids |
| Dehydration | D003681 | 11 associated lipids |
| Demyelinating Diseases | D003711 | 15 associated lipids |
| Dental Enamel Hypoplasia | D003744 | 2 associated lipids |
| Dental Pulp Calcification | D003784 | 2 associated lipids |
| Dermatitis | D003872 | 30 associated lipids |
| Drug Eruptions | D003875 | 30 associated lipids |
| Dermatitis, Atopic | D003876 | 19 associated lipids |
| Dermatitis, Contact | D003877 | 59 associated lipids |
tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
- Antimicrob. Agents Chemother. (2)
- Am. J. Physiol. Renal Physiol. (1)
- Drug Metab. Dispos. (1)
- Others (1)
| Disease | Cross reference | Weighted score | Related literature |
|---|
Loading... please refresh the page if content is not showing up.
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
Loading... please refresh the page if content is not showing up.
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| David-Neto E et al. | Longitudinal Pharmacokinetics of Everolimus When Combined With Low-level of Tacrolimus in Elderly Renal Transplant Recipients. | 2017 | Transplantation | pmid:27798513 |
| Jain A et al. | Pregnancy after liver transplantation under tacrolimus. | 1997 | Transplantation | pmid:9293865 |
| Farid SG et al. | Alemtuzumab (Campath-1H)-induced coagulopathy in renal transplantation. | 2009 | Transplantation | pmid:19502974 |
| Garcia-Criado FJ et al. | Tacrolimus (FK506) down-regulates free radical tissue levels, serum cytokines, and neutrophil infiltration after severe liver ischemia. | 1997 | Transplantation | pmid:9293871 |
| Satterthwaite R et al. | Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. | 1998 | Transplantation | pmid:9484771 |
| Stevens RB et al. | Randomized trial of single-dose versus divided-dose rabbit anti-thymocyte globulin induction in renal transplantation: an interim report. | 2008 | Transplantation | pmid:18497677 |
| Heeckt PF et al. | Functional impairment of enteric smooth muscle and nerves caused by chronic intestinal allograft rejection regresses after FK506 rescue. | 1995 | Transplantation | pmid:7530870 |
| Gruessner RW et al. | A prospective study of FK506 versus CsA and pig ATG in a porcine model of small bowel transplantation. | 1995 | Transplantation | pmid:7530871 |
| Jindal RM et al. | Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506. | 1994 | Transplantation | pmid:7514317 |
| Todo S et al. | Abdominal multivisceral transplantation. | 1995 | Transplantation | pmid:7530873 |
| Arns W et al. | Pharmacokinetics and Clinical Outcomes of Generic Tacrolimus (Hexal) Versus Branded Tacrolimus in De Novo Kidney Transplant Patients: A Multicenter, Randomized Trial. | 2017 | Transplantation | pmid:28658202 |
| Sheikh AM et al. | Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. | 1999 | Transplantation | pmid:10440408 |
| Lawsin L and Light JA | Severe acute renal failure after exposure to sirolimus-tacrolimus in two living donor kidney recipients. | 2003 | Transplantation | pmid:12544890 |
| Furukawa H et al. | Prolongation of canine liver allograft survival by a novel immunosuppressant, FTY720: effect of monotherapy and combined treatment with conventional drugs. | 2000 | Transplantation | pmid:10670633 |
| Moxey-Mims MM | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1999 | Transplantation | pmid:10440413 |
| Jordan ML et al. | Results of pancreas transplantation after steroid withdrawal under tacrolimus immunosuppression. | 2000 | Transplantation | pmid:10670637 |
| Hodge G et al. | Lymphocytic bronchiolitis is associated with inadequate suppression of blood T-cell granzyme B, IFN-gamma, and TNF-alpha. | 2010 | Transplantation | pmid:20559033 |
| Asako H et al. | Reduction of leukocyte adherence and emigration by cyclosporine and L683,590 (FK506) in postcapillary venules. | 1992 | Transplantation | pmid:1384191 |
| Yun J et al. | Bilateral ischemic optic neuropathy in a patient using tacrolimus (FK506) after liver transplantation. | 2010 | Transplantation | pmid:20559109 |
| Fujita T et al. | Prolonged survival of rat skin allograft by treatment with FK506 ointment. | 1997 | Transplantation | pmid:9326422 |
| Kato T et al. | Rhabdomyolysis after kidney transplantation caused by elevated serum cyclosporine due to metabolic enzyme and transporters disorder. | 2011 | Transplantation | pmid:21747275 |
| Pratschke J et al. | Treatment of cyclosporine-related adverse effects by conversion to tacrolimus after liver transplantation. | 1997 | Transplantation | pmid:9326428 |
| Ashokkumar C et al. | Allospecific CD154+ T-cytotoxic memory cells identify recipients experiencing acute cellular rejection after renal transplantation. | 2011 | Transplantation | pmid:21747326 |
| McGhee B et al. | Therapeutic use of an extemporaneously prepared oral suspension of tacrolimus in pediatric patients. | 1997 | Transplantation | pmid:9326429 |
| High KP | The antimicrobial activities of cyclosporine, FK506, and rapamycin. | 1994 | Transplantation | pmid:7517076 |
| Berenguer M et al. | Effect of calcineurin inhibitors in the outcome of liver transplantation in hepatitis C virus-positive recipients. | 2010 | Transplantation | pmid:21068701 |
| Cosio FG et al. | Comparison of low versus high tacrolimus levels in kidney transplantation: assessment of efficacy by protocol biopsies. | 2007 | Transplantation | pmid:17318073 |
| Yoshimura N et al. | The direct effect of FK506 and rapamycin on interleukin 1(beta) and immunoglobulin production in vitro. | 1994 | Transplantation | pmid:7517078 |
| Valdivia LA et al. | Successful hamster-to-rat liver xenotransplantation under FK506 immunosuppression induces unresponsiveness to hamster heart and skin. | 1993 | Transplantation | pmid:7681230 |
| Shapiro R et al. | A prospective randomized trial of FK506-based immunosuppression after renal transplantation. | 1995 | Transplantation | pmid:7533343 |
| Cox KL et al. | An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation. | 1995 | Transplantation | pmid:7533344 |
| Sakr M et al. | The protective effect of FK506 pretreatment against renal ischemia/reperfusion injury in rats. | 1992 | Transplantation | pmid:1374948 |
| Casey MJ et al. | Prolonged immunosuppression preserves nonsensitization status after kidney transplant failure. | 2014 | Transplantation | pmid:24717218 |
| Maes BD et al. | Posttransplantation diabetes mellitus in FK-506-treated renal transplant recipients: analysis of incidence and risk factors. | 2001 | Transplantation | pmid:11726827 |
| Stifft F et al. | Lower variability in 24-hour exposure during once-daily compared to twice-daily tacrolimus formulation in kidney transplantation. | 2014 | Transplantation | pmid:24686426 |
| Kahan BD | An immunosuppressive triumvirate to minimize renal injuries associated with calcineurin antagonist therapy. | 1999 | Transplantation | pmid:10428260 |
| Washburn K et al. | Steroid elimination 24 hours after liver transplantation using daclizumab, tacrolimus, and mycophenolate mofetil. | 2001 | Transplantation | pmid:11726831 |
| Toso C et al. | Insulin independence after conversion to tacrolimus and sirolimus-based immunosuppression in islet-kidney recipients. | 2003 | Transplantation | pmid:14557767 |
| Moxey-Mims MM et al. | Increased incidence of insulin-dependent diabetes mellitus in pediatric renal transplant patients receiving tacrolimus (FK506) | 1998 | Transplantation | pmid:9521193 |
| Vu MD et al. | Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. | 2003 | Transplantation | pmid:12792496 |
| Tzakis AG et al. | Alemtuzumab (Campath-1H) combined with tacrolimus in intestinal and multivisceral transplantation. | 2003 | Transplantation | pmid:12792506 |
| Peloso LJ et al. | The serum concentration of tacrolimus after ingesting omeprazole: a pilot study. | 2014 | Transplantation | pmid:25221905 |
| Koenen HJ et al. | Superior T-cell suppression by rapamycin and FK506 over rapamycin and cyclosporine A because of abrogated cytotoxic T-lymphocyte induction, impaired memory responses, and persistent apoptosis. | 2003 | Transplantation | pmid:12792519 |
| Hytiroglou P et al. | FK506 versus cyclosporine as primary immunosuppressive agent for orthotopic liver allograft recipients. Histologic and immunopathologic observations. | 1993 | Transplantation | pmid:7506452 |
| Jain A et al. | Pharmacokinetics of tacrolimus in living donor liver transplant and deceased donor liver transplant recipients. | 2008 | Transplantation | pmid:18347534 |
| Gallon L et al. | Differential Effects of Calcineurin and Mammalian Target of Rapamycin Inhibitors on Alloreactive Th1, Th17, and Regulatory T Cells. | 2015 | Transplantation | pmid:25905982 |
| Castells L et al. | Liver transplantation in HIV-HCV coinfected patients: a case-control study. | 2007 | Transplantation | pmid:17297413 |
| Alhamad T et al. | Targeting High Calcineurin Inhibitor Levels After Acute Rejection With Less Tremor: A New Strategy. | 2017 | Transplantation | pmid:28422926 |
| Hill CC et al. | Penile prosthesis surgery in the immunosuppressed patient. | 1993 | Transplantation | pmid:7692633 |
| Yanchar NL et al. | Tacrolimus (FK506)--its effects on intestinal glucose transport. | 1996 | Transplantation | pmid:8610392 |
| Johansson A and Möller E | Evidence that the immunosuppressive effects of FK506 and cyclosporine are identical. | 1990 | Transplantation | pmid:1701570 |
| Hariharan S et al. | Rescue therapy with tacrolimus after combined kidney/pancreas and isolated pancreas transplantation in patients with severe cyclosporine nephrotoxicity. | 1996 | Transplantation | pmid:8610411 |
| Robertsen I et al. | Use of generic tacrolimus in elderly renal transplant recipients: precaution is needed. | 2015 | Transplantation | pmid:25148382 |
| Reyes J et al. | Expressive dysphasia possibly related to FK506 in two liver transplant recipients. | 1990 | Transplantation | pmid:1701571 |
| Khanna AK | Mechanism of the combination immunosuppressive effects of rapamycin with either cyclosporine or tacrolimus. | 2000 | Transplantation | pmid:10972232 |
| Koh A et al. | Supplemental islet infusions restore insulin independence after graft dysfunction in islet transplant recipients. | 2010 | Transplantation | pmid:20145529 |
| Shapiro R et al. | Pediatric renal transplantation under tacrolimus-based immunosuppression. | 1999 | Transplantation | pmid:10075598 |
| Königsrainer A et al. | Nonocclusive segmental mesenteric ischemia after combined pancreas kidney transplantation: mycophenolate mofetil as an etiological factor? | 2000 | Transplantation | pmid:10972233 |
| Sofi AA et al. | Bullous pemphigoid associated with acute renal allograft rejection. | 2010 | Transplantation | pmid:20145531 |
| Kaplan B et al. | Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal P-glycoprotein activity. | 1999 | Transplantation | pmid:10075604 |
| Min DI et al. | Circadian variation of tacrolimus disposition in liver allograft recipients. | 1996 | Transplantation | pmid:8900327 |
| Jindal RM et al. | Diabetogenicity of FK506 versus cyclosporine in liver transplant recipients. | 1994 | Transplantation | pmid:7519799 |
| Mor E et al. | Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression. | 1994 | Transplantation | pmid:7519800 |
| Merkle M et al. | The effect of sevelamer on tacrolimus target levels. | 2005 | Transplantation | pmid:16177649 |
| McDevitt-Potter LM et al. | A multicenter experience with generic tacrolimus conversion. | 2011 | Transplantation | pmid:21788920 |
| Demmers MW et al. | Substantial proliferation of human renal tubular epithelial cell-reactive CD4+CD28null memory T cells, which is resistant to tacrolimus and everolimus. | 2014 | Transplantation | pmid:24157471 |
| Dickenmann MJ et al. | Blood eosinophilia in tacrolimus-treated patients: an indicator of Pneumocystis carinii pneumonia. | 1999 | Transplantation | pmid:10589963 |
| Eckhoff DE et al. | Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. | 1998 | Transplantation | pmid:9458011 |
| Roth D et al. | Primary immunosuppression with tacrolimus and mycophenolate mofetil for renal allograft recipients. | 1998 | Transplantation | pmid:9458023 |
| Zhao W et al. | Pharmacokinetic interaction between tacrolimus and amlodipine in a renal transplant child. | 2012 | Transplantation | pmid:22450597 |
| Jacobson PA et al. | Genetic and clinical determinants of early, acute calcineurin inhibitor-related nephrotoxicity: results from a kidney transplant consortium. | 2012 | Transplantation | pmid:22334041 |
| Schneeberger S et al. | Cytomegalovirus-related complications in human hand transplantation. | 2005 | Transplantation | pmid:16123716 |
| Ciancio G et al. | A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. | 2005 | Transplantation | pmid:16123718 |
| Woodle ES et al. | FK506: inhibition of humoral mechanisms of hepatic allograft rejection. | 1992 | Transplantation | pmid:1379749 |
| Thorp M et al. | The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism and cholesterol. | 2000 | Transplantation | pmid:10762229 |
| Murase N et al. | Hamster-to-rat heart and liver xenotransplantation with FK506 plus antiproliferative drugs. | 1993 | Transplantation | pmid:7682735 |
| Sulanc E et al. | New-onset diabetes after kidney transplantation: an application of 2003 International Guidelines. | 2005 | Transplantation | pmid:16249743 |
| Laskow DA et al. | An open-label, concentration-ranging trial of FK506 in primary kidney transplantation: a report of the United States Multicenter FK506 Kidney Transplant Group. | 1996 | Transplantation | pmid:8878381 |
| Mourad M et al. | Sirolimus and tacrolimus trough concentrations and dose requirements after kidney transplantation in relation to CYP3A5 and MDR1 polymorphisms and steroids. | 2005 | Transplantation | pmid:16249748 |
| Woodle ES et al. | Tacrolimus therapy for refractory acute renal allograft rejection: definition of the histologic response by protocol biopsies. | 1996 | Transplantation | pmid:8878382 |
| Macedo C et al. | Long-term effects of alemtuzumab on regulatory and memory T-cell subsets in kidney transplantation. | 2012 | Transplantation | pmid:22343334 |
| Tanaka A et al. | Living related liver transplantation across ABO blood groups. | 1994 | Transplantation | pmid:7522363 |
| Rodriguez Rilo HL et al. | Rapid hair regrowth in refractory alopecia universalis associated with autoimmune disease following liver transplantation and tacrolimus (FK506) therapy. | 1995 | Transplantation | pmid:7539169 |
| Ko S et al. | The enhanced immunosuppressive efficacy of newly developed liposomal FK506 in canine liver transplantation. | 1995 | Transplantation | pmid:7539553 |
| Klein IH et al. | Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. | 2002 | Transplantation | pmid:11907418 |
| Vincenti F et al. | A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. | 2002 | Transplantation | pmid:11907427 |
| Ringe B et al. | A novel management strategy of steroid-free immunosuppression after liver transplantation: efficacy and safety of tacrolimus and mycophenolate mofetil. | 2001 | Transplantation | pmid:11258429 |
| Klein A et al. | Impact of a pharmaceutical care program on liver transplant patients' compliance with immunosuppressive medication: a prospective, randomized, controlled trial using electronic monitoring. | 2009 | Transplantation | pmid:19300186 |
| Beckebaum S et al. | Predictive factors of outcome in patients transplanted for hepatitis B. | 2009 | Transplantation | pmid:19300191 |
| Pascual J et al. | Authors' reply: cyclosporine A versus tacrolimus in steroid withdrawal strategies. | 2011 | Transplantation | pmid:21336083 |
| Lorber MI et al. | A comparison of in vivo responses to cyclosporine, FK506, and rapamycin following allogeneic immune challenge. | 1991 | Transplantation | pmid:1713364 |
| Abu-Elmagd K et al. | The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. | 1991 | Transplantation | pmid:1713365 |
| Konrad T et al. | Regulation of glucose tolerance in patients after liver transplantation: impact of cyclosporin versus tacrolimus therapy. | 2000 | Transplantation | pmid:10852599 |
| Fredericks S and Holt DW | TGF-beta quantitation can be tricky. | 1999 | Transplantation | pmid:10480399 |
| Schvarcz R et al. | Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV and hepatitis C virus (HCV). | 2000 | Transplantation | pmid:10852623 |
| Cacciarelli TV et al. | Management of posttransplant lymphoproliferative disease in pediatric liver transplant recipients receiving primary tacrolimus (FK506) therapy. | 1998 | Transplantation | pmid:9808490 |
| Macphee IA et al. | Tacrolimus pharmacogenetics: the CYP3A5*1 allele predicts low dose-normalized tacrolimus blood concentrations in whites and South Asians. | 2005 | Transplantation | pmid:15729180 |
| Letavernier E et al. | Proteinuria following a switch from calcineurin inhibitors to sirolimus. | 2005 | Transplantation | pmid:16314786 |
| Baggio B et al. | Relationship between plasma phospholipid polyunsaturated fatty acid composition and bone disease in renal transplantation. | 2005 | Transplantation | pmid:16314806 |
| Wai LE et al. | Rapamycin, but not cyclosporine or FK506, alters natural killer cell function. | 2008 | Transplantation | pmid:18192925 |